Commentary

Cancer systems biology unleashed: From molecules to mechanisms

Aminah A Barqawi 1,*

1 University, College of Science, Department of Chemistry, Makkah Al -Mukarramah, P.O. 6287, 21955, Saudi Arabia.

* Correspondence: aabbarqawi@uqu.edu.sa (A.A.B.)

Citation: Barqawi, A.A. Cancer systems biology unleashed: From molecules to mechanisms. Glob. Jour. Bas. Sci. 2025, 1(8). 1-4.

Received: April 25, 2025

Revised: May 11, 2025

Accepted: May 12, 2025

Published: May 12, 2025

doi: 10.63454/jbs20000032

ISSN: 3049-3315

Volume 1; Issue 7

Download PDF file

Abstract: Cancer is a multifaceted disease driven by complex interactions among genetic, epigenetic, metabolic, and microenvironmental factors. Traditional reductionist approaches, which focus on individual genes or pathways, have provided valuable insights but fall short in explaining tumor heterogeneity, adaptive resistance, and disease progression. Cancer systems biology has emerged as a powerful paradigm that integrates high-throughput omics data with computational and mathematical modeling to understand cancer as a dynamic, interconnected system. This commentary discusses how systems biology is transforming cancer research by bridging molecular components to higher-order mechanisms, enabling network-level insights, predictive modeling, and precision oncology. We highlight key advances, current challenges, and future opportunities in unleashing the full potential of cancer systems biology.

Keywords: Cancer systems biology; Network medicine; Omics integration; Tumor heterogeneity; Precision oncology

1. Introduction

Cancer remains one of the most challenging diseases of the modern era, not because of a lack of molecular information, but due to the overwhelming complexity of how molecular events interact to drive disease behavior. Over the past decades, remarkable advances in genomics and molecular biology have identified thousands of cancer-associated genes, mutations, and signaling pathways. Yet, despite this wealth of data, the translation of molecular discoveries into durable clinical success has been limited [1-3].  This disconnect has led to a fundamental shift in perspective—from viewing cancer as a collection of isolated molecular defects to recognizing it as a systems-level disease. Cancer systems biology has emerged at this intersection of biology, computation, and medicine, aiming to understand how interactions among molecules give rise to emergent cellular and tissue-level behaviors. By integrating data across multiple biological layers, systems biology moves “from molecules to mechanisms,” offering a holistic framework to decode cancer complexity [4-5].

2. Limitations of Reductionist Cancer Research

Reductionist approaches have been instrumental in identifying oncogenes, tumor suppressors, and hallmark pathways such as PI3K/AKT, MAPK, p53, and Wnt signaling. Targeted therapies developed against single molecular drivers initially showed promise; however, many patients experience relapse due to adaptive resistance, pathway redundancy, or clonal evolution.

Cancer cells do not operate through linear pathways but through interconnected signaling networks with feedback loops and compensatory mechanisms. Inhibiting one node often leads to network rewiring, allowing tumors to survive and progress. Furthermore, tumor heterogeneity—both inter- and intra-tumoral—cannot be adequately captured by single-gene analyses. These limitations underscore the need for systems-level approaches that consider the collective behavior of molecular components [4-7].

3. Cancer systems biology: a network-centric view

Cancer systems biology conceptualizes tumors as complex adaptive systems governed by interconnected networks of genes, proteins, metabolites, and signaling pathways. Instead of examining isolated molecular components, this framework emphasizes how interactions among these elements, along with network topology and dynamic behavior, collectively shape cancer development and progression [1,3,4,8-10]. 

Through network analysis, systems biology enables the identification of key regulatory hubs that exert disproportionate control over cellular behavior. It also reveals recurring network motifs and feedback loops that can either stabilize malignant states or drive transitions toward more aggressive phenotypes (Figure 1). These structural and dynamic features are critical for understanding how cancer cells maintain survival, proliferation, and resistance under varying conditions. A central insight from this approach is the recognition of emergent properties, such as robustness and adaptability, which arise from collective network interactions rather than from any single molecule. These properties help explain why cancer systems can tolerate genetic mutations, environmental stress, and therapeutic interventions while maintaining viability[1-3,10]. 

Importantly, cancer systems biology demonstrates that therapeutic vulnerabilities often reside in network dependencies rather than individual targets. Disrupting critical network interactions or dependencies may therefore produce more durable and effective responses compared to conventional single-target therapies, offering a promising direction for next-generation cancer treatment strategies [2,7,11-17].

Figure 1. Cancer systems biology: From molecules to mechanisms. A simple layout to show multi-omics data integration via insilco approach to personalised treatment.

4. From omics data to mechanistic insight
The rapid evolution of high-throughput technologies has been a major driving force behind advances in cancer systems biology. Modern multi-omics platforms now enable comprehensive and simultaneous profiling of tumors at an unprecedented level of resolution, capturing the molecular complexity that underlies cancer behavior. Different omics layers provide complementary insights into tumor biology. Genomics identifies mutations, copy number alterations, and structural variations that initiate or promote malignant transformation. Transcriptomics reveals gene expression programs and regulatory states that define tumor phenotypes, while proteomics and phosphoproteomics directly measure protein abundance and signaling activity, offering a closer view of functional cellular processes [2,8,11-13]. In parallel, metabolomics reflects the metabolic states of cancer cells, linking molecular alterations to bioenergetic and biosynthetic demands. Systems biology integrates these diverse data layers to reconstruct regulatory and signaling networks and to infer causal relationships among molecular components. By combining experimental data with computational modeling—ranging from statistical and network-based approaches to mechanistic and machine-learning-driven frameworks—systems biology transforms raw, high-dimensional data into testable mechanistic hypotheses. This integrative strategy allows researchers to move beyond descriptive catalogs of alterations toward a predictive understanding of cancer behavior, therapeutic response, and disease evolution.

5. Tumor heterogeneity and evolution through a systems lens

One of the most powerful contributions of cancer systems biology is its capacity to address tumor heterogeneity and evolutionary dynamics. Tumors are not uniform entities; rather, they are composed of diverse subclonal populations that continuously evolve under selective pressures imposed by the tumor microenvironment, immune surveillance, and therapeutic interventions. Systems-level analyses illuminate how distinct clonal populations interact, cooperate, or compete within the tumor ecosystem. These approaches also reveal how stress-response and survival networks are activated in response to therapy, allowing certain subclones to persist despite treatment [1-3, 13-22]. In addition, systems biology uncovers the roles of epigenetic and metabolic plasticity in enabling cancer cells to switch phenotypes, adapt to hostile conditions, and escape therapeutic constraints. By modeling cancer as a dynamic and evolving system, systems biology provides critical insights into the mechanisms underlying drug resistance and disease relapse. This perspective not only explains why initially effective therapies often fail but also helps identify rational strategies—such as combination treatments or adaptive therapy designs—to prevent or delay therapeutic failure and improve long-term clinical outcomes.

5. The Tumor Microenvironment as a System Component

Cancer systems biology extends beyond tumor cells to include the tumor microenvironment (TME)—a complex ecosystem of immune cells, stromal cells, cytokines, and extracellular matrix. Systems approaches capture bidirectional interactions between cancer cells and their surroundings, revealing how inflammation, hypoxia, and immune evasion shape tumor behavior.  Network-based studies of the TME have highlighted critical communication pathways that promote angiogenesis, metastasis, and immune suppression. These insights are guiding the development of combination strategies that target both tumor-intrinsic and microenvironment-driven mechanisms.

6. Implications for precision oncology

Perhaps the most transformative impact of cancer systems biology lies in precision medicine. Rather than matching patients to therapies based on single biomarkers, systems approaches enable patient-specific network modeling. This allows prediction of drug response, identification of optimal drug combinations, and stratification of patients based on system-level vulnerabilities.  By integrating clinical data with molecular networks, systems biology supports a shift from reactive to predictive oncology—where treatment decisions are informed by an understanding of how an individual tumor system is likely to respond and adapt [22-30].

7. The tumor microenvironment as a system component

Despite its considerable promise, cancer systems biology faces several significant challenges. Integrating diverse datasets remains complex due to differences in scale, data noise, temporal resolution, and experimental platforms. In addition, computational models must strike a careful balance between biological realism and interpretability, while experimental validation of system-level predictions is often time-consuming, technically demanding, and resource-intensive. Future progress in the field will depend on several key advances [18-19]. The availability of standardized, high-quality multi-omics datasets will be essential for robust and reproducible analyses. At the same time, continued development of improved computational frameworks—including AI- and machine-learning–driven models—will enhance the ability to extract meaningful insights from high-dimensional data. Equally important is the closer integration of experimental, computational, and clinical research to ensure that systems-level discoveries translate into tangible clinical benefit. 

Education and collaboration across disciplinary boundaries will also play a critical role, as effective cancer systems biology requires expertise spanning biology, medicine, mathematics, computer science, and engineering. As these challenges are progressively addressed, systems biology is poised to become a cornerstone of cancer research and therapy, enabling more predictive, precise, and durable treatment strategies.

8. Conclusions

Cancer systems biology represents a paradigm shift in how we understand and tackle cancer. By embracing complexity and focusing on interactions rather than isolated components, it bridges the gap between molecular data and disease mechanisms. Moving from molecules to mechanisms, this approach offers deeper biological insight, explains clinical failures of reductionist strategies, and opens new avenues for precision oncology. As technologies and models continue to evolve, unleashing the full potential of cancer systems biology will be essential for transforming cancer research into meaningful clinical impact.

Author Contributions: Conceptualisation, A.A.B.; software, A.A.B.; investigation, A.A.B.;  writing—original draft preparation, A.A.B.; writing—review and editing, A.A.B.; visualisation, A.A.B.; supervision, A.A.B.; project administration, A.A.B. The author has read and agreed to the published version of the manuscript.

Funding: Not applicable.

Acknowledgments: We are grateful to the University, College of Science, Department of Chemistry, Makkah Al -Mukarramah, Saudi Arabia for providing us all the facilities to carry out the entire work.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: All the related data are supplied in this work or have been referenced properly.

References

  1. Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: The next generation. Cell, 144(5), 646–674.
  2. Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013). Cancer genome landscapes. Science, 339(6127), 1546–1558.
  3. Barabási, A. L., Gulbahce, N., & Loscalzo, J. (2011). Network medicine: A network-based approach to human disease. Nature Reviews Genetics, 12(1), 56–68.
  4. Kitano, H. (2002). Systems biology: A brief overview. Science, 295(5560), 1662–1664.
  5. Sever, R., & Brugge, J. S. (2015). Signal transduction in cancer. Cold Spring Harbor Perspectives in Medicine, 5(4), a006098.
  6. Ideker, T., & Krogan, N. J. (2012). Differential network biology. Molecular Systems Biology, 8, 565.
  7. Kreeger, P. K., & Lauffenburger, D. A. (2010). Cancer systems biology. Annual Review of Biomedical Engineering, 12, 167–193.
  8. Califano, A., et al. (2012). Network-based approaches to cancer biology. Nature Reviews Genetics, 13(9), 596–610.
  9. Margolin, A. A., et al. (2006). ARACNE: An algorithm for the reconstruction of gene regulatory networks. BMC Bioinformatics, 7, S7.
  10. Hopkins, A. L. (2008). Network pharmacology: The next paradigm in drug discovery. Nature Chemical Biology, 4(11), 682–690.
  11. Manning, B. D., & Toker, A. (2017). AKT/PKB signaling: Navigating the network. Cell, 169(3), 381–405.
  12. Dhillon, A. S., Hagan, S., Rath, O., & Kolch, W. (2007). MAP kinase signalling pathways in cancer. Oncogene, 26(22), 3279–3290.
  13. Yu, H., Pardoll, D., & Jove, R. (2009). STATs in cancer inflammation and immunity. Nature Reviews Cancer, 9(11), 798–809.
  14. Clevers, H. (2006). Wnt/β-catenin signaling in development and disease. Cell, 127(3), 469–480.
  15. Karin, M. (2009). NF-κB as a critical link between inflammation and cancer. Cold Spring Harbor Perspectives in Biology, 1(5), a000141.
  16. Esteller, M. (2008). Epigenetics in cancer. New England Journal of Medicine, 358(11), 1148–1159.
  17. Baylin, S. B., & Jones, P. A. (2016). Epigenetic determinants of cancer. Cold Spring Harbor Perspectives in Biology, 8(9), a019505.
  18. Quail, D. F., & Joyce, J. A. (2013). Microenvironmental regulation of tumor progression. Nature Medicine, 19(11), 1423–1437.
  19. Hanahan, D., & Coussens, L. M. (2012). Accessories to the crime: Tumor microenvironment. Cancer Cell, 21(3), 309–322.
  20. Gupta, P. B., et al. (2009). Cancer stem cells: Mirror of normal development. Nature Medicine, 15(9), 1010–1012.
  21. Greaves, M., & Maley, C. C. (2012). Clonal evolution in cancer. Nature, 481(7381), 306–313.
  22. Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013). Cancer drug resistance. Nature Reviews Cancer, 13(10), 714–726.
  23. Al-Lazikani, B., Banerji, U., & Workman, P. (2012). Combinatorial drug therapy for cancer. Nature Biotechnology, 30(7), 679–692.
  24. Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017). Cancer nanomedicine. Nature Reviews Cancer, 17(1), 20–37.
  25. Zhang, Z., et al. (2019). Systems biology of cancer: From networks to models. Briefings in Bioinformatics, 20(2), 379–391.
  26. Kibble, M., Saarinen, N., Tang, J., Wennerberg, K., Mäkelä, S., & Aittokallio, T. (2015). Network pharmacology applications. Nature Reviews Drug Discovery, 14(7), 512–520.
  27. Subramanian, A., et al. (2017). A next-generation connectivity map. Cell, 171(6), 1437–1452.
  28. Sanchez-Vega, F., et al. (2018). Oncogenic signaling pathways in The Cancer Genome Atlas. Cell, 173(2), 321–337.
  29. Tibshirani, R., et al. (2015). Personalized medicine and systems biology. Proceedings of the National Academy of Sciences, 112(27), 8332–8337.
  30. Hood, L., & Friend, S. H. (2011). Predictive, personalized, preventive, and participatory (P4) cancer medicine. Nature Reviews Clinical Oncology, 8(3), 184–187.

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of Global Journal of Basic Science and/or the editor(s). Global Journal of Basic Science and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. 

Copyright: © 2025 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

Loading

Bibliography